Point72 Asset Management
ATNM icon

Point72 Asset Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Point72 Asset Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,295
Closed -$14K – 3769
2025
Q4 		$14K Buy
+10,295
New +$15K ﹤0.01% 3840

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's ATNM Position: Q1 2026 in Review

Point72 Asset Management sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 10,295 shares — an estimated $14K sold.

Point72 Asset Management first reported a position in ATNM in Q4 2025 and held it in 1 quarter. The position peaked at $14K in Q4 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Point72 Asset Management reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 10,295 Actinium Pharmaceuticals shares in Q1 2026, an estimated $14K.
  • Point72 Asset Management first reported a position in Actinium Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Point72 Asset Management's Actinium Pharmaceuticals position peaked at $14K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.